Literature DB >> 7554381

Chloroquine inhibits T cell proliferation by interfering with IL-2 production and responsiveness.

R B Landewé1, A M Miltenburg, M J Verdonk, C L Verweij, F C Breedveld, M R Daha, B A Dijkmans.   

Abstract

Chloroquine (Chl) is an anti-rheumatic drug that is widely used in the treatment of rheumatoid arthritis (RA). It seems that T cells are important in the pathogenesis of RA, but it is not known whether Chl acts via inhibition of T cell function. We here present evidence that Chl, just like cyclosporine A (CsA), inhibits T cell proliferation as induced with immobilized alpha CD3 MoAb in a concentration-dependent manner, at least partly through interfering with the production of IL-2 protein and the induction of IL-2 mRNA. Furthermore, Chl impedes the responsiveness of T cell clones to IL-2 since (1) the inhibition of alpha CD3 MoAb-induced proliferation by Chl could not be reversed by rIL-2 and (2) Chl directly blocks IL-2-driven proliferation of cloned T cells. Chl appeared to interfere with the internalization (50% inhibition) and degradation (total blockade) of rIL-2. Finally, the combination of Chl and CsA synergistically inhibited T cell proliferation. We conclude that Chl may inhibit functional properties of human T cells, although the drug is 100- to 1000-fold less potent than CsA in inhibiting T cell proliferation and IL-2 production, respectively. It is speculated that the in vitro effects of Chl might be relevant in explaining the anti-rheumatic effect of this drug in patients with RA.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7554381      PMCID: PMC1553352          DOI: 10.1111/j.1365-2249.1995.tb06648.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Predominantly T-cell infiltrate in rheumatoid synovial membranes.

Authors:  J A Van Boxel; S A Paget
Journal:  N Engl J Med       Date:  1975-09-11       Impact factor: 91.245

Review 2.  Synergy, additivism and antagonism in immunosuppression. A critical review.

Authors:  M C Berenbaum
Journal:  Clin Exp Immunol       Date:  1977-04       Impact factor: 4.330

Review 3.  The effects of cyclosporin A on the immune system.

Authors:  E M Shevach
Journal:  Annu Rev Immunol       Date:  1985       Impact factor: 28.527

4.  Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4'-bis(diethylaminoethoxy) alpha, beta-diethyldiphenylethane.

Authors:  Y Matsuzawa; K Y Hostetler
Journal:  J Biol Chem       Date:  1980-06-10       Impact factor: 5.157

5.  Chloroquine and ammonium ion inhibit receptor-mediated endocytosis of mannose-glycoconjugates by macrophages: apparent inhibition of receptor recycling.

Authors:  C Tietze; P Schlesinger; P Stahl
Journal:  Biochem Biophys Res Commun       Date:  1980-03-13       Impact factor: 3.575

6.  Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway.

Authors:  S C Meuer; R E Hussey; D A Cantrell; J C Hodgdon; S F Schlossman; K A Smith; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1984-03       Impact factor: 11.205

7.  Pharmacologic actions of 4-aminoquinoline compounds.

Authors:  A H Mackenzie
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

8.  Immunosuppressive potential of antimalarials.

Authors:  G Salmeron; P E Lipsky
Journal:  Am J Med       Date:  1983-07-18       Impact factor: 4.965

9.  In vivo and in vitro action of chloroquine on surface markers of human peripheral lymphocytes.

Authors:  P S Nagarkatti; M Nagarkatti; V C Jain
Journal:  Clin Exp Immunol       Date:  1980-07       Impact factor: 4.330

10.  Interactions of chloroquine with different glycerophospholipids.

Authors:  A Harder; S Kovatchev; H Debuch
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1980-12
View more
  18 in total

1.  Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.

Authors:  Pascale M Abena; Eric H Decloedt; Emmanuel Bottieau; Fatima Suleman; Prisca Adejumo; Nadia A Sam-Agudu; Jean-Jacques Muyembe TamFum; Moussa Seydi; Serge P Eholie; Edward J Mills; Oscar Kallay; Alimuddin Zumla; Jean B Nachega
Journal:  Am J Trop Med Hyg       Date:  2020-06       Impact factor: 2.345

2.  Anti-inflammatory activity of chloroquine and amodiaquine through p21-mediated suppression of T cell proliferation and Th1 cell differentiation.

Authors:  Sera Oh; Ji Hyun Shin; Eun Jung Jang; Hee Yeon Won; Hyo Kyeong Kim; Mi-Gyeong Jeong; Kwang Soo Kim; Eun Sook Hwang
Journal:  Biochem Biophys Res Commun       Date:  2016-04-22       Impact factor: 3.575

3.  Chloroquine stimulates nitric oxide synthesis in murine, porcine, and human endothelial cells.

Authors:  D Ghigo; E Aldieri; R Todde; C Costamagna; G Garbarino; G Pescarmona; A Bosia
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 4.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

5.  Chloroquine inhibits human CD4+ T-cell activation by AP-1 signaling modulation.

Authors:  Ralf L J Schmidt; Sabrina Jutz; Katrin Goldhahn; Nadine Witzeneder; Marlene C Gerner; Doris Trapin; Georg Greiner; Gregor Hoermann; Guenter Steiner; Winfried F Pickl; Heinz Burgmann; Peter Steinberger; Franz Ratzinger; Klaus G Schmetterer
Journal:  Sci Rep       Date:  2017-02-07       Impact factor: 4.379

Review 6.  Neutrophil Extracellular Traps (NETs) and Damage-Associated Molecular Patterns (DAMPs): Two Potential Targets for COVID-19 Treatment.

Authors:  Sebastiano Cicco; Gerolamo Cicco; Vito Racanelli; Angelo Vacca
Journal:  Mediators Inflamm       Date:  2020-07-16       Impact factor: 4.711

7.  Immunity to malaria in Plasmodium vivax infection: a study in central China.

Authors:  Kulachart Jangpatarapongsa; Hui Xia; Qiang Fang; Kaiming Hu; Yuanying Yuan; Meiyu Peng; Qi Gao; Jetsumon Sattabongkot; Liwang Cui; Baiqing Li; Rachanee Udomsangpetch
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

Review 8.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

Review 9.  Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?

Authors:  Priyanka Pahan; Kalipada Pahan
Journal:  J Neuroimmune Pharmacol       Date:  2020-05-15       Impact factor: 4.147

10.  Could Chloroquine /Hydroxychloroquine Be Harmful in Coronavirus Disease 2019 (COVID-19) Treatment?

Authors:  Maurizio Guastalegname; Alfredo Vallone
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.